Related Experiment Video
Updated: Oct 5, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Is cannabidiol worth a trial in Rasmussen encephalitis?
Christine Prager1, Fabienne Kühne1, Anna Tietze2
1Charité - Universitätsmedizin Berlin, Department of Pediatric Neurology, Augustenburger Platz 1, 13353, Berlin, Germany; Charité - Universitätsmedizin Berlin, Center for Chronically Sick Children (Sozialpädiatrisches Zentrum, SPZ), Augustenburger Platz 1, 13353, Berlin, Germany.
Cannabidiol shows promise for treating drug-resistant epilepsy in Rasmussen encephalitis. This treatment, added to existing antiseizure medications, demonstrated significant positive effects in three pediatric patients.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Background:
- Rasmussen encephalitis is a rare, chronic inflammatory neurological disease.
- It often leads to drug-resistant focal epilepsy in children and adolescents.
- Current treatment options for severe cases are limited.
Purpose of the Study:
- To evaluate the efficacy of cannabidiol as an add-on therapy for drug-resistant epilepsy in patients with Rasmussen encephalitis.
- To assess the impact of cannabidiol on seizure frequency and severity in this specific patient population.
Main Methods:
- Case series involving three pediatric patients diagnosed with Rasmussen encephalitis.
- Patients received cannabidiol as an adjunctive treatment alongside their established antiseizure medications (ASMs).
- Clinical outcomes, including seizure control, were monitored.
Main Results:
- All three patients experienced a positive therapeutic effect from cannabidiol.
- The observed efficacy appeared to exceed that of previously used fourth or fifth-line antiseizure drugs.
- Cannabidiol demonstrated significant potential in managing refractory seizures associated with Rasmussen encephalitis.
Conclusions:
- Cannabidiol may represent a valuable therapeutic option for pediatric patients with drug-resistant epilepsy secondary to Rasmussen encephalitis.
- Further research, including larger controlled trials, is warranted to confirm these preliminary findings.
- Add-on cannabidiol therapy shows promise in improving seizure control in this challenging neurological condition.
